Every letter we have printed

I would like the trade to adopt a convention on significant figures. A specification of not less than 98 per cent and a result of 98.04 per cent are a pass by two hundredths of a point, which is well inside the repeatability of the method. The certificate should carry the method repeatability alongside the limit, or the pass means nothing.

On the difference between a release specification and a shelf-life specification: outside a regulated setting almost nobody distinguishes them, and it matters. A limit that a lot met on the day it was made is not a promise about the lot in the drawer eighteen months later, and the certificate is a photograph rather than a warranty.

The absence that costs buyers most is peptide content. Purity tells you what fraction of what is there is the right molecule; content tells you how much is there at all. Every reconstitution calculation depends on the second and almost every certificate reports only the first.

Appearance is the most under-rated line on the page. It is a genuine observation, it is free, and a cake described as white when the vial in front of you is faintly yellow tells you something has happened between the two. Everything else on the certificate requires an instrument to argue with.

An approved schedule is a regulatory artefact reflecting what was submitted and what was studied, and it is read as a statement about what is optimal. Those are different things and the gap between them is not evidence of anything.

The material this publication covers has no label at all, which makes the whole comparison a read-across from a different product. Saying so plainly, as you do, is more useful than the comparison itself.

Writing the calculation out longhand once, on paper, and keeping it, is worth more than any tool. It creates a record that can be re-read later, which is the thing a calculator conspicuously does not produce.

The stated content of a vial is the assumption everything else rests on, and it is exactly the quantity this publication has shown is least often independently determined. The arithmetic can be perfect and still produce the wrong answer.

You spend a page on the four-line calculation and then publish a reconstitution table anyway. Are you not providing exactly the pre-computed number you warned against?

The stopper wipe is the step with the best evidence behind it and the one most often skipped, presumably because the vial looks clean. Contact time matters as much as the wipe: alcohol needs to dry to have done anything.

A sterile field is a concept and not a product. The bench, the hands, the air movement and the sequence all belong to it, and a person working carefully on a clean surface is doing more than one working carelessly with expensive supplies.

The commonest reason for an intermittent pattern is supply or cost rather than design, which means much of what looks like a strategy is an accommodation. Reporting it as a strategy misdescribes what is happening.

Intermittent use is studied almost nowhere and practised widely, which is an uncomfortable combination for anybody trying to write about it responsibly. The honest position is that the evidence base is close to empty, and saying so is more useful than assembling anecdotes.

Reference change value is the concept that would help most people here, and almost nobody outside laboratory medicine has heard of it. It combines analytical and biological variation into a threshold for a meaningful difference.

Where a result is flagged high or low, the flag is generated by software against the interval and carries no clinical judgement whatsoever. Readers treat the flag as an opinion and it is a comparison.

The reason I have most often encountered is a simple one and appears in no list: it was always meant to be temporary. Somebody who set out to stop and then stopped has not discontinued in any interesting sense, and they are counted alongside those who did.

The distinction between stopping and pausing is made by the person and not by the data. Somebody who intends to resume is recorded as a discontinuation, and the two populations behave very differently afterwards.

I stopped eight months ago after reaching a weight I was happy with, and I have regained four of the twenty-two kilograms I lost. Every article I read told me to expect two-thirds back. I am not complaining, but I would like to know whether I am unusual or whether the two-thirds figure was always a mean concealing an enormous range.

The published trials that continued longest are the ones least discussed, presumably because their results are the least dramatic. A quiet extension study is more informative about a long commitment than any headline finding from a twelve-month arm.

Reading this issue end to end, the thing that struck me is how often the answer is that nobody has looked. It is a depressing finding and it is plainly the true one.

Tamper-evident packaging costs a few pence and would answer most of the questions custody is meant to answer. A sealed bag with a serial number that the laboratory records on receipt is not a chain of custody and it is a great deal better than nothing.

The point your piece makes about documentation applies to custody with more force. A supplier that publishes its own handling record gives a buyer something to check; a supplier that publishes only a result gives them something to believe.

The periprocedural guidance in this area moved quickly and the underlying evidence did not, which produced a period in which different professional bodies said different things about the same question. That history is worth documenting because it explains the current disagreement.

Anything in this area is squarely a matter for the clinician conducting the procedure, and a publication’s job is to describe what the professional guidance says and where it differs. Yours does that and stops, which is right.

Hydration advice is given universally and is more important where symptoms include losses, which is not everybody. Blanket recommendations tend to be repeated past the point where they apply, and specifying the situation would improve them.

Escalation schedules in the published trials were chosen for study logistics as much as for tolerability, and they have since been read as optimal. There is very little published work comparing schedules head to head.

The ethics of a withdrawal design deserve a sentence somewhere. Randomising somebody to lose an effect they have obtained is defensible and it is not trivial, and the consent process for these studies is more interesting than the results.

Participants who complete a run-in and are then randomised are a selected group by construction, so the withdrawal arm is populated by people who tolerated and responded. Generalising from them to everybody who stops overstates what is known.

On archived certificates: ask for the previous three lots as well as the current one. A single document is a snapshot and tells you nothing about drift, and three consecutive ones will tell you more about the manufacturer than any individual figure on any of them.

A note from the laboratory side. We are frequently sent a sample with a request to confirm a figure from another laboratory’s report, and we are almost never sent that report. Without it we cannot match the method, so the comparison the customer wanted is not the comparison they get.

Certificates travel. A document issued for one lot, scanned and reissued for a later one, is indistinguishable from a fresh one unless you compare the determination date against the fill date. I have received two identical scans with different lot numbers typed over the same figure.

Injection site affects absorption for compounds of this kind, and the effect size is published for some of them. It is one of the few practical variables with actual data behind it and it is discussed less than several with none.

Exposure varies several-fold between individuals at the same nominal input, which means any statement relating a dose to an effect is a statement about a population average. The variability is published and rarely quoted.

A plateau is a physiological outcome rather than a failure of dosing, and the reflex to escalate at that point is worth examining. Your piece hints at this and could say it outright: the curve flattening is what the curve does.

Where the material is of uncertain content, an apparent plateau may be a supply event rather than a physiological one. That possibility exists in this market and in no clinical trial, and it deserves to be named in any coverage aimed at these readers.

A statistical point. Regression to the mean will produce an apparent plateau after any period of unusually rapid change, and none of the observational accounts in circulation control for it.

Maintenance at a reduced dose has a thin evidence base compared with the escalation and target-dose literature, which is the opposite of where most people spend their time. That imbalance deserves stating every time maintenance is discussed.

A last point about this publication’s own framing. Research-use material is not approved for human use in any jurisdiction, and a maintenance discussion conducted around such material is a discussion about a supply chain rather than about a therapy. Keeping that distinction visible is the useful thing you do.

I take this for kidney disease, not for weight. Every piece of writing I encounter about stopping is about the weight coming back. It has taken me a year to find anybody willing to say plainly that the renal benefit accrued over years of treatment and nobody has tested what happens if I stop.

The protein intake figures in general circulation come largely from resistance-training studies in energy balance, and applying them to a substantial energy deficit is an extrapolation in the direction of needing more rather than less. Your article says this and most coverage does not.